Detailed frequency of JAK2V617F mutation in different cohorts, stratified by PV, MF and ET, or not (*)
| JAK2V617F+/tested | |||||
|---|---|---|---|---|---|
| Authors | PV | MF | ET | Total | JAK2V617F Frequency (%) |
| Monte-Mór et al7 | 47/49 | 14/25 | 8/29 | 69/103 | 66.9 |
| Baxter et al8 | 71/73 | 8/16 | 29/51 | 108/140 | 77.1 |
| James et al9 | 40/45 | 3/7 | 9/21 | 52/73 | 71.2 |
| Kralovics et al10 | 83/128 | 13/23 | 21/93 | 117/244 | 47.9 |
| Levine et al11 | 121/164 | 16/46 | 37/115 | 174/325 | 53.5 |
| dos Santos et al12 | 18/20 | 9/21 | 8/17 | 35/58 | 60.3 |
| Kiladjian et al*13 | No stratification | 94/241 | 39.0 | ||
| This study* | No stratification | 28/78 | 35.9 | ||
ET, Essential thrombocythemia; MF, myelofibrosis; PV, polycythaemia vera.
*There was no stratification for PV, MF or ET on both studies.